Reckitt-Benckiser Q1
This article was originally published in The Rose Sheet
Executive Summary
Revenue for firm's health and personal-care division advanced 4% to roughly $797.5 mil. for the fiscal 2010 first quarter, with strong growth in personal-care product sales, driven by Lysol No Touch Hand Soap System and Veet depilatories in North America and Dettol antiseptic products in international markets, U.K.-based company reports April 27. Performance of personal-care brands was offset by the impact of a weak cold/flu season in North America and Europe, which kept down sales of Mucinex congestion relief and Strepcils sore-throat lozenges, according to Reckitt. Firm's net sales were $3.05 bil., representing an increase of 6% compared with the prior-year period, and net income increased 17% to $529.6 mil
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.